BASF Plant Science identifies case of low level comingling in Amflora fields in Sweden
In-house quality control identifies small quantity of Amadea potatoes in Amflora fields
BASF Plant Science identified extremely small quantities of Amadea potatoes in Amflora fields planted in Northern Sweden during the course of the regular inhouse quality controls. The Swedish competent authority was informed at the end of August after BASF Plant Science employees identified Amadea plants in Amflora fields during regular control visits. The fields in question have been planted for seed multiplication of the genetically modified starch potato Amflora.
Amadea is BASF’s second starch potato variety that was submitted last week for regulatory approval in the EU by BASF Plant Science. The level of comingling is less than 0.01%, which translates to 47 Amadea plants among approximately 680,000 Amlora plants. BASF Plant Science removed all Amadea plants from the fields. The subsequent steps are currently under discussion with the relevant authorities including the European Commission.
The cause of the low level comingling of Amadea is currently being thoroughly analyzed. The comingling was identified because Amadea flowers are white, while Amflora only develops a few violet flowers. All Amadea plants have been removed during the growth period and did not enter the commercial starch production. Amflora fields in Germany and the Czech Republic were also monitored in the course of the regular stewardship controls. No Amadea potatoes were identified in these fields.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Modeling NAFLD with human pluripotent stem cell derived immature hepatocyte like cells
Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor - Award to Chinese Scientist Supports the Use of Various Molecular Approaches to Cancer Research
Vitamins doing gymnastics: Scientists capture first full image of vitamin B12 in action - Work by University of Michigan and MIT team yields new understanding of crucial reaction in the body and in CO2-scrubbing bacteria
Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment
Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
